140 related articles for article (PubMed ID: 32919000)
21. Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers.
Esslinger HU; Köhne S; Radziwon P; Walenga JM; Breddin HK
Clin Appl Thromb Hemost; 2003 Jan; 9(1):79-88. PubMed ID: 12643328
[TBL] [Abstract][Full Text] [Related]
22. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition.
Mo W; Zhang YL; Chen HS; Wang LS; Song HY
J Thromb Thrombolysis; 2009 Aug; 28(2):230-7. PubMed ID: 18998199
[TBL] [Abstract][Full Text] [Related]
23. Efficient targeted anticoagulant with active RGD motif.
Bi Q; Zhou X; Cen X; Qu H; Luo J; Huang Y; Zhu S
Thromb Res; 2007; 120(4):541-7. PubMed ID: 17222892
[TBL] [Abstract][Full Text] [Related]
24. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
Lu WF; Mo W; Liu Z; Fu WG; Guo DQ; Wang YQ; Song HY
Thromb Res; 2010 Oct; 126(4):e339-43. PubMed ID: 20483158
[TBL] [Abstract][Full Text] [Related]
25. Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein.
Ren K; Gong H; Huang J; Liu Y; Dong Q; He K; Tian L; Zhang F; Yu A; Wu C
Thromb Res; 2021 Dec; 208():26-34. PubMed ID: 34688099
[TBL] [Abstract][Full Text] [Related]
26. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
van Wyk V; Neethling WM; Badenhorst PN; Kotzé HF
J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
[TBL] [Abstract][Full Text] [Related]
27. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty.
Meyer BJ; Fernández-Ortiz A; Mailhac A; Falk E; Badimon L; Michael AD; Chesebro JH; Fuster V; Badimon JJ
Circulation; 1994 Nov; 90(5):2474-80. PubMed ID: 7955205
[TBL] [Abstract][Full Text] [Related]
28. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Meddahi S; Samama MM
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
[TBL] [Abstract][Full Text] [Related]
29. Quantitative determination of hirudin in blood and body fluids.
Nowak G; Bucha E
Semin Thromb Hemost; 1996; 22(2):197-202. PubMed ID: 8807717
[TBL] [Abstract][Full Text] [Related]
30. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
31. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity.
Bode AP; Lust RM
Thromb Res; 1994 Mar; 73(5):285-300. PubMed ID: 7517074
[TBL] [Abstract][Full Text] [Related]
32. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin.
Wallén NH; Ladjevardi M; Albert J; Bröijersén A
Thromb Res; 1997 Jul; 87(1):151-7. PubMed ID: 9253810
[TBL] [Abstract][Full Text] [Related]
33. Effect of the hirudin carboxy-terminal peptide 54-65 on the interaction of thrombin with platelets.
Jandrot-Perrus M; Huisse MG; Krstenansky JL; Bezeaud A; Guillin MC
Thromb Haemost; 1991 Sep; 66(3):300-5. PubMed ID: 1746000
[TBL] [Abstract][Full Text] [Related]
34. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
Prager NA; Abendschein DR; McKenzie CR; Eisenberg PR
Circulation; 1995 Aug; 92(4):962-7. PubMed ID: 7641380
[TBL] [Abstract][Full Text] [Related]
35. Investigation on recombinant hirudin via oral route.
Cen X; Ni J; Tan T; Liu X; Li C; Chen J; Huang Y; Zhu S; Bi Q
Peptides; 2006 Apr; 27(4):836-40. PubMed ID: 16469415
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Multiplate platelet aggregometry using citrate, heparin or hirudin in Rhesus macaques.
Dugan G; O'Donnell L; Hanbury DB; Cline JM; Caudell DL
Platelets; 2015; 26(8):730-5. PubMed ID: 25549285
[TBL] [Abstract][Full Text] [Related]
37. Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity.
Yu A; Zhang C; Dong C; Yu H; Zhong G; Wang L; Wu C
Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1955-61. PubMed ID: 19256345
[TBL] [Abstract][Full Text] [Related]
38. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia.
Longrois D; de Maistre E; Bischoff N; Dopff C; Meistelman C; Angioï M; Lecompte T
Can J Anaesth; 2000 Mar; 47(3):255-60. PubMed ID: 10730738
[TBL] [Abstract][Full Text] [Related]
39. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa.
Peter K; Graeber J; Kipriyanov S; Zewe-Welschof M; Runge MS; Kübler W; Little M; Bode C
Circulation; 2000 Mar; 101(10):1158-64. PubMed ID: 10715263
[TBL] [Abstract][Full Text] [Related]
40. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
